evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3,703 questions · 3,824 findings · 858 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 573 · 15%GRADE not reported 383 · 10%Very low 993 · 26%Low 1,062 · 27.8%Moderate 614 · 16.1%High 199 · 5.2%

Pre‐emptive antifungal therapy vs empirical antifungal therapy

Duration of antifungal use (days) · people with cancer who have febrile neutropenia

It is very uncertain whether pre‐emptive antifungal therapy changes duration of antifungal use (days) compared with empirical antifungal therapy (very low certainty).

1 finding from 1 review

Short‐acting inhaled beta‐2 agonists vs placebo

Number of exacerbations(as reported by number of hospitalisations and number of courses and days on antibiotics) · adults and children with cystic fibrosis

It is very uncertain whether short‐acting inhaled beta‐2 agonists changes number of exacerbations(as reported by number of hospitalisations… compared with placebo (very low certainty).

1 finding from 1 review

Endovascular therapy plus conventional medical treatment vs medical treatment

Death or stroke · people with vertebral artery stenosis

Endovascular treat ment plus medical treatment showed no clear difference in 30‐day post‐randomisation death/stroke compared with medical treatment alone (low certainty).

1 finding from 1 review

Endovascular therapy plus conventional medical treatment vs medical treatment

Fatal/non‐fatal stroke in the territory of the treated vertebral artery stenosis(assessed after 30 days post‐randomisation to completion of · people with vertebral artery stenosis

Endovascular treat ment plus medical treatment showed no clear difference in fatal/non‐fatal stroke in the territory of the treated vertebral… compared with medical treatment alone (moderate certainty).

1 finding from 1 review

Casirivimab/imdevimab vs placebo

Development of clinical COVID‐19 symptoms within 30 days · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2

Casirivimab/imdevimab leads to lower development of clinical COVID‐19 symptoms within 30 days compared with placebo (high certainty).

1 finding from 1 review

Summary of findings table ‐ Corticosteroids plus standard care vs placebo or usual care

All‐cause mortality up to 30 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

Summary of findings table ‐ Corticosteroids plus standard care probably leads to lower all‐cause mortality up to 30 days compared with standard care (plus/minus placebo) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)

All‐cause mortality up to 30 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in all‐cause mortality up to 30 days compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).

1 finding from 1 review

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)

All‐cause mortality up to 120 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19

It is very uncertain whether summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) changes all‐cause mortality up to 120 days compared with low‐dose dexamethasone (6 mg to 8 mg) (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Corticosteroids plus standard care vs placebo or usual care

All‐cause mortality up to 120 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

It is very uncertain whether summary of findings table ‐ Corticosteroids plus standard care changes all‐cause mortality up to 120 days compared with standard care (plus/minus placebo) (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Methylprednisolone vs dexamethasone

All‐cause mortality up to 30 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

It is very uncertain whether summary of findings table ‐ Methylprednisolone changes all‐cause mortality up to 30 days compared with dexamethasone (very low certainty).

1 finding from 1 review

Intervention not reported

All‐cause mortality at day 28 · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…

It is very uncertain whether the intervention changes all‐cause mortality at day 28 (very low certainty).

1 finding from 1 review